Search results for "Pain measurement"

showing 10 items of 358 documents

Pain Perception and Stabilometric Parameters in People With Chronic Low Back Pain After a Pilates Exercise Program

2016

Various exercise interventions, such as Pilates exercises and traditional physical therapy methods, are employed to decrease low back pain (LBP). Nonspecific low back pain (NSLBP) is distinct from LBP, however, as the distribution of pain is restricted to the region between the costal margin and the inferior gluteal. The aim of our randomized controlled trial was to evaluate the effects of a program of Pilates exercises on pain perception and stabilometric parameters in patients with NSLBP. Thirty-eight participants were randomly allocated, using a 1:1 scheme, to either the experimental group (EG) or control group (CG). The EG completed a 14-week program of Pilates exercises, performed thri…

MaleSeverity of Illness Indexlaw.inventionDisability Evaluation0302 clinical medicineRandomized controlled triallawProspective Studies030212 general & internal medicineProspective cohort studyPain MeasurementMedicine (all)StatisticsChronic painPain PerceptionGeneral MedicineMiddle AgedPrognosisLow back painOswestry Disability IndexTreatment OutcomePatient SatisfactionExercise Movement TechniquesFemaleChronic Painmedicine.symptomExercise Movement TechniqueSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieHumanAdultmedicine.medical_specialtyPrognosiStatistics Nonparametric03 medical and health sciencesPatient satisfactionPhysical medicine and rehabilitationSeverity of illnessmedicineHumansAdult; Chronic Pain; Exercise Movement Techniques; Female; Humans; Low Back Pain; Male; Middle Aged; Pain Measurement; Pain Perception; Patient Satisfaction; Prognosis; Prospective Studies; Severity of Illness Index; Statistics Nonparametric; Treatment Outcome; Disability Evaluation; Medicine (all)NonparametricSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' Sportivebusiness.industryPosturographymedicine.diseaseProspective StudiePhysical therapybusinessLow Back Pain030217 neurology & neurosurgeryMedicine
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct

Hyperalgesia and opioid switching

2005

Opioids, intended to abolish pain, can unexpectedly produce hyperalgesia, particularly during rapid opioid escalation. Opioid switching could be a therapeutic option in a condition of opioid-induced tolerance or hyperalgesia, but conversion ratios between opioids are difficult to apply in this context and require strict surveillance and expertise. This situation is challenging, because the rapid escalation of opioid doses, possibly due to the development of opioid-induced tolerance, can cause hyperalgesia. To avoid this adverse effect, clinicians need to refine their assessment of pain treatment and consider opioid switching. The authors present a case report in which switching from fentan…

MaleTime FactorsPainContext (language use)Drug Administration ScheduleFentanyl03 medical and health sciences0302 clinical medicine030502 gerontologymedicineHumansAdverse effectPain Measurementbusiness.industryPatient SelectionPalliative CareSarcomaDrug ToleranceGeneral MedicineMiddle AgedThoracic NeoplasmsAnalgesics OpioidFentanylTherapeutic EquivalencyOpioidHyperalgesia030220 oncology & carcinogenesisAnesthesiaHyperalgesiaDrug Monitoringmedicine.symptom0305 other medical scienceCancer painbusinessMethadonemedicine.drugMethadoneAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Assessment of pre and postoperative anxiety in patients undergoing ambulatory oral surgery in primary care.

2017

Background To analyze the pre- and postoperative anxiety level in patients undergoing ambulatory oral surgery (AOS) in a primary healthcare center (PHC). Material and Methods Prospective and descriptive clinical study on 45 patients who underwent AOS procedures in the dental clinic of a public PHC of Spain between April and September 2015. Anxiety analysis was carried out with pre- and postoperative anxiety-state (STAI-S), anxiety-trait (STAI-T) and dental anxiety (MDAS) questionnaires. A descriptive, inferential and binary logistic regression analysis were performed for the variables age, sex, educational level, previous experience of oral treatment, type of oral surgery, degree of third m…

MaleTooth extractionTrait050109 social psychologyAnxietySTAI scale0302 clinical medicineMedicineLongitudinal StudiesProspective Studiesambulatory surgeryProspective cohort studyPain MeasurementImpactionIncidence (epidemiology)05 social sciencesAmbulatory Surgical Procedure:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in DentistryAmbulatoryUNESCO::CIENCIAS MÉDICASAnxietyFemalemedicine.symptompostoperative painDental anxietyState anxietyoral surgeryAdultmedicine.medical_specialtyVisual analogue scalePreoperative care3rd molarprimary care03 medical and health sciencesInternal medicinePreoperative CareHumans0501 psychology and cognitive sciencesGeneral DentistryPostoperative CarePrimary Health Carebusiness.industryResearch030206 dentistryOtorhinolaryngologyAmbulatory Surgical ProceduresSurgerybusinessRemoval
researchProduct

Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

2016

Background and objective: Statin-induced myopathy (SIM) has been partially attributed to deficiency of dolichol and coenzyme Q10 (CoQ10). We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM. Materials and methods: In an open-label, one-center prospective pilot study patients with SIM received conifer-tree needle polyprenols (4 mg/day) and CoQ10 (100 mg/day) for 8 weeks. Symptoms and safety were evaluated according to symptom severity score (0–10), creatine kinase (CK) levels, exercise test, dynamometry, complete blood count, clinical biochemistry and electrocardiography. Results: Of the 14 patients, 11 completed the study per protoc…

MaleUbiquinoneMyopathyPilot Projects030204 cardiovascular system & hematologyGastroenterologyElectrocardiography0302 clinical medicine030212 general & internal medicineProspective StudiesProspective cohort studyPain MeasurementAged 80 and overMedicine(all)lcsh:R5-920Muscle Weaknessbiologymedicine.diagnostic_testComplete blood countMiddle AgedTreatment OutcomeDrug Therapy CombinationFemalemedicine.symptomlcsh:Medicine (General)Glomerular Filtration Ratemedicine.medical_specialtyStatinmedicine.drug_classRenal functionAsymptomaticPolyprenols03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMyopathyAgedbusiness.industryTerpenesStatinsMyalgiamedicine.diseaseTracheophytaAutomotive EngineeringPhysical therapybiology.proteinExercise TestCoenzyme Q10Creatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessStatins; Myopathy; Polyprenols; Coenzyme Q10; UbiquinoneBiomarkersKidney diseaseMedicina
researchProduct

Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome

2010

Current IASP diagnostic criteria for CRPS have low specificity, potentially leading to overdiagnosis. This validation study compared current IASP diagnostic criteria for CRPS to proposed new diagnostic criteria (the "Budapest Criteria") regarding diagnostic accuracy. Structured evaluations of CRPS-related signs and symptoms were conducted in 113 CRPS-I and 47 non-CRPS neuropathic pain patients. Discriminating between diagnostic groups based on presence of signs or symptoms meeting IASP criteria showed high diagnostic sensitivity (1.00), but poor specificity (0.41), replicating prior work. In comparison, the Budapest clinical criteria retained the exceptional sensitivity of the IASP criteria…

MaleValidation studymedicine.medical_specialtyDatabases FactualSigns and symptomsDiagnostic accuracySensitivity and SpecificityArticleDiagnosis DifferentialmedicineRegional pain syndromeHumansOverdiagnosisPain Measurementbusiness.industryReproducibility of ResultsComplex Regional Pain Syndrome Reflex sympathetic dystrophy CRPS RSD Diagnosis Validation reflex sympathetic dystrophy syndrome type-i signs crpsmedicine.diseaseSurgeryAnesthesiology and Pain MedicineComplex regional pain syndromeNeurologyPhysical therapyFemaleNeurology (clinical)businessComplex Regional Pain Syndromes
researchProduct

The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients

2012

Abstract OBJECTIVES: The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only. METHODS: A multicenter prospective randomized controlled study was carried out in a sample of 70 advanced cancer patients with pain requiring strong opioids. Thirty-five patients (group MO) were randomized to receive sustained-release morphine using initial doses of 60 mg/day. Thirty-five patients (group MO-PR) were randomized to start the same morphine doses and pregabalin in increasing doses, starting with 25 mg/day up to 150 mg/day in one week. The follo…

Malecancer painAnalgesicPregabalinPregabalinPainSettore MED/42 - Igiene Generale E Applicatalaw.inventionDose-Response Relationshipadvanced cancer patientDrug TherapyQuality of lifeRandomized controlled triallawassessment toolsNeoplasmsmedicineHumansDrug Interactionslow doses pregabalinBrief Pain Inventorygamma-Aminobutyric AcidPain Measurementneuropathic painAnalgesicsDose-Response Relationship DrugMorphinebusiness.industryassessment tools; cancer pain; neuropathic pain; opioid response; Analgesics; Dose-Response Relationship Drug; Drug Interactions; Drug Therapy Combination; Female; Humans; Italy; Male; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Pregabalin; Treatment Outcome; gamma-Aminobutyric Acid; Anesthesiology and Pain Medicine; Neurology (clinical)Palliative CareAdvanced cancerTreatment OutcomeAnesthesiology and Pain MedicineItalyOpioidlow doses pregabalin; advanced cancer patients; epidemiologic studyopioid responseAnesthesiaCombinationepidemiologic studyMorphineDrug Therapy CombinationFemaleNeurology (clinical)Drugbusinessmedicine.drug
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Breakthrough pain in patients with abdominal cancer pain.

2014

Abstract OBJECTIVE: Characterization of breakthrough cancer pain (BTcP) in patients with abdominal cancer is lacking. The aim of this study was to assess the characteristics of BTcP in patients with abdominal cancer pain. PATIENTS AND METHODS: In an observational cohort study, from a consecutive sample of patients admitted to a pain relief and supportive care unit for a period of 13 months, patients with abdominal disease due to cancer, including primary cancer or metastases, were assessed for the presence of chronic abdominal pain; its mechanism, intensity of background pain, and pain flares, which were distinguishable from the baseline pain, were recorded. Patients presenting with pain fl…

Malecancer painmedicine.medical_specialtyPalliative careAnalgesicSettore MED/41 - AnestesiologiaDiseaseSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsInternal medicinemedicineHumansPain ManagementIn patientcancer pain; breakthrough pain; abdominal pain; epidemiology; opioidsNeoplasm MetastasisAgedPain MeasurementAnalgesicsbusiness.industryPalliative Careabdominal painopioidsCancerbreakthrough painmedicine.diseaseAnesthesiology and Pain MedicineFemaleepidemiologyObservational studyNeurology (clinical)Chronic PainCancer painbusinessCohort study
researchProduct